Short Implants in Atrophic Posterior Maxilla

Short Implant Placement for Single-Tooth Rehabilitation in the Atrophic Posterior Maxilla

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06759246

Enrollment

150

Registered

2025-01-06

Start date

2014-01-01

Completion date

2024-11-01

Last updated

2025-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Atrophy, Alveolar, Edentulism, Sinus Pneumatization

Keywords

short implants, bone atrophy, sinus pneumatization, minimal invasive

Brief summary

This study aims to evaluate the clinical and radiological outcomes of short implants in the rehabilitation of single-tooth edentulism in the posterior maxilla. By assessing these outcomes, the research seeks to determine the effectiveness and long-term viability of short implants as a minimally invasive solution, particularly in cases where bone height is limited.

Detailed description

The present municentric retrospective study was conducted following the STROBE statement recommendations for observational studies and in compliance to the principles of the Declaration of Helsinki on clinical research involving human subjects.The study aims to evaluate short implants placed over the past 15 years by three experienced clinicians, assessing their survival and clinical success. Specifically, the study collects clinical data such as probing depth, the presence or absence of peri-implantitis, and radiological findings.

Interventions

PROCEDUREimplant placement

Placement of short implants for the rehabilitation of single-tooth edentulism in atrophic maxillae near the maxillary sinus.

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Good health status according to the classification system of the American Society of Anesthesiology (ASA), and patients were required to be 18 years of age or older. * No general medical condition that would contraindicate implant therapy. * No active periodontal disease, defined as a periodontal probing depth of less than 4 mm, or previously treated periodontitis. * Good oral hygiene, with a full-mouth plaque index of less than 25%. * Adequate control of inflammation, with a full-mouth bleeding on probing (BOP) of less than 25%.

Exclusion criteria

* Smoking more than 15 cigarettes per day * Presence of untreated periodontal disease * Pregnancy or breastfeeding at the time of enrollment * Active infections * Less than 2 mm of keratinized mucosal tissue.

Design outcomes

Primary

Measure	Time frame	Description
Clinical outcome	2 years	Survival rate: A statistical analysis will be conducted to evaluate the implant survival rate at three specific time points: T1 (3 months), T2 (6 months), and T3 (2 years).

Secondary

Measure	Time frame	Description
Rx outcome	2 years	Radiographic measurements will be obtained using standardized imaging techniques. The measurements will be performed digitally using dedicated three-dimensional radiological imaging software, ensuring high precision. Distances will be measured in millimeters to evaluate implant positioning, bone levels, and defect morphology with accuracy.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026